<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924898</url>
  </required_header>
  <id_info>
    <org_study_id>CID 0805 (PHI 02)</org_study_id>
    <nct_id>NCT00924898</nct_id>
  </id_info>
  <brief_title>Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)</brief_title>
  <official_title>CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of treatment of acute HIV infection with a once daily regimen of
      Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are:

        1. To determine the safety and tolerability, and the virologic and immunologic efficacy of
           FTC, TDF, and efavirenz given once daily to patients with acute HIV infection.

        2. To assess the impact of once daily therapy combined with a standardized adherence
           program on treatment adherence, virologic suppression, and rate of viral load decline in
           blood and infectious fluids (semen, cervico-vaginal secretions).

        3. To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents
           among persons diagnosed with acute HIV infection in the Southeastern United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Once daily ART with fixed dose combination FTC/TDF/EFV will reduce viral
      replication to &lt;200 copies RNA/ml plasma in blood and other body compartments in patients
      with acute HIV infection, reducing infectivity. The treatment regimen will be well tolerated
      during treatment follow-up. A coordinated program of counseling and support will facilitate
      adherence and promote successful therapy. Prevalence of transmitted drug resistant HIV-1 will
      be assessed.

      Study Design: Dual-center, prospective, single-arm pilot study of FTC/TDF/EFV in patients
      with acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection
      Study Consortium. Patients will be followed intensively for 96 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Without Virologic Failure at Week 24</measure>
    <time_frame>HIV RNA level prior to or at week 24 following enrollment</time_frame>
    <description>Number of participants with a HIV RNA level &lt;200 copies/mL at week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Without Virologic Failure at Week 48</measure>
    <time_frame>HIV RNA level at week 48 following enrollment</time_frame>
    <description>HIV RNA level &lt;50 copies/mL at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Suppression at Week 96</measure>
    <time_frame>HIV RNA level at 96 weeks following enrollment</time_frame>
    <description>Number of participants wtih HIV RNA level &lt;50 copies/mL at week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications</measure>
    <time_frame>At enrollment</time_frame>
    <description>Prevalence of any of the surveillance drug resistance mutations associated with resistance to antiretroviral medications listed by the World Health Organization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment</measure>
    <time_frame>At enrollment</time_frame>
    <description>Baseline genotypic resistance defined as presence of any surveillance drug resistance mutation to any drug in the study treatment listed by the World Health Organization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HIV RNA Suppression &lt;50 Copies/mL</measure>
    <time_frame>Number of days from start of study treatment until HIV RNA suppression, assessed through week 96</time_frame>
    <description>Number of days from ART initiation to HIV RNA suppression &lt;50 copies/mL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Acute HIV Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Acute HIV Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz, emtricitabine, and tenofovir</intervention_name>
    <description>Once daily ART with emtricitabine, tenofovir DF and efavirenz</description>
    <arm_group_label>Acute HIV Treatment Group</arm_group_label>
    <other_name>Tenofovir disoproxil fumarate</other_name>
    <other_name>Emtricitabine</other_name>
    <other_name>FDC Emtricitabine 200 mg/ tenofovir 300 mg</other_name>
    <other_name>Efavirenz</other_name>
    <other_name>FDC Emtricitabine 200mg/Tenofovir 300mg DF/Efavirenz 600mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of acute HIV infection as defined by protocol.

          2. The following laboratory parameters verified within 30 days of study entry:

               -  Bilirubin &lt;/= 3.0mg/dL

               -  ALT/AST &lt;/= 10 X upper limit of normal

               -  Absolute neutrophil count (ANC) &gt;/= 500cells/mm3

               -  Platelet count &gt;/= 25,000 cells/mm3

               -  Hemoglobin &gt;/= 8.5g/dL for men and &gt;/= 8.0 g/dL for women

               -  Calculated creatinine clearance (Cockcroft-Gault formula) &gt;/= 50mL/min:

             CrCl = (140-age) x body weight (kg) (x 0.85 if female)/ Serum creatinine [mg/dL] x
             (72)

          3. All women of child-bearing potential (WOCBP) must have a negative serum or urine
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of bHCG) within 72
             hours prior to start of study medication. WOCBP is defined as any female who has
             experienced menarche and who has not undergone successful surgical sterilization
             (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), who is not
             postmenopausal (defined as amenorrhea &gt;/=12 consecutive months), or is on hormone
             replacement therapy (HRT) with documented plasma follicle-stimulating hormone level
             &gt;/=35mLU/mL. Women who are using oral, implanted, or injectable contraceptive hormones
             or mechanical products such as an intrauterine device or barrier methods (diaphragm,
             condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner
             is sterile (e.g., vasectomy), should be considered to be of child bearing potential;

          4. Be willing to use two effective forms of contraception throughout study. Barrier
             contraception should always be used in combination with other methods of contraception
             (oral or other hormonal contraceptives);

          5. Weigh &gt;/= 40 kg;

        Exclusion Criteria:

          1. A life expectancy less than twelve months.

          2. Women who are pregnant or breastfeeding.

          3. Women with a positive pregnancy test on enrollment or prior to study drug
             administration.

          4. WOCBP who are unwilling or unable to use two acceptable methods to avoid pregnancy for
             the entire study period

          5. WOCBP using a prohibited contraceptive method

          6. Hypersensitivity to any component of the formulation of study drugs.

          7. A clinically important illness not explicitly excluded by the protocol, a physical or
             psychiatric disability, or a laboratory abnormality that might place the patient at
             increased risk by being exposed to the medications in this study or which might
             confound the interpretation of this investigation.

          8. Proven or suspected acute hepatitis within 30 days prior to study entry (this excludes
             liver inflammation related to acute HIV infection).

          9. Intractable diarrhea (&gt;/=6 loose stools/day for at least 7 consecutive days) within 30
             days prior to study entry or vomiting lasting more than 4 days within one month prior
             to dosing (this excludes symptoms attributed to acute HIV infection).

         10. An active AIDS-defining opportunistic infection or disease (for the purpose of this
             study, a CD4 count &lt;/=200 cells/mm3 in the absence of any other AIDS-defining
             indicator condition is not considered an AIDS-defining event. AIDS-defining events
             occurring during the acute HIV infection syndrome period such as Candida esophagitis
             will be considered on a case-by-case basis and will not be automatically considered
             exclusionary).

         11. Inability to communicate effectively with study personnel.

         12. Current alcohol or recreational drug use which in the investigator's opinion
             interferes with the subject's ability to comply with dosing schedule and protocol
             evaluations or increases the risk of developing pancreatitis.

         13. Incarceration; prisoner recruitment and participation are not permitted.

         14. Difficulty swallowing capsules/tablets.

         15. Prior treatment with any other experimental drug for any indication (within 30 days of
             initiating study treatment).

         16. Treatment with immune-modulating agents (within 30 days of initiating study treatment)
             such as cyclosporine and systemic corticosteroids. Routine vaccinations are allowed.

         17. Therapy with agents with significant systemic neurotoxic pancreotropic or cytotoxic
             potential within 3 months of study start, or the need for such therapy is expected at
             the time of enrollment.

         18. Therapy with nephrotoxic agents (aminoglycosides, IV amphotericin, cidofovir, IV
             pentamidine, cisplatin other agents with nephrotoxic potential), adefovir or
             probenecid. These agents must be discontinued at least 30 days prior to starting study
             medications. Brief course of aminoglycosides within 30 days of enrollment may be
             allowed after discussion with Study Chairs.

         19. Concomitant Medications:

               -  The following medications are expressly prohibited during the course of the
                  trial: Astemizole, cisapride, ergot derivatives, hydroxyurea, midazolam,
                  thalidomide, triazolam, vincristine, zalcitabine, ribavirin, doxorubicin,
                  Voriconazole, St. John's wort or any medications that are contraindicated for
                  concomitant use as described in the current product information packet insert for
                  the ARV therapies used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Gay, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aids2008.org/abstract.aspx?elementId=200714266</url>
    <description>IAS Conference Abstract-Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection</description>
  </link>
  <reference>
    <citation>Gay CL, Willis SJ, Cope AB, Kuruc JD, McGee KS, Sebastian J, Crooks AM, McKellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium. Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. AIDS. 2016 Nov 28;30(18):2815-2822.</citation>
    <PMID>27662549</PMID>
  </reference>
  <results_reference>
    <citation>C Gay, A Johnson, S McCoy, J Kuruc, K McGee, L McNeil, M Kerkau, J Sebastian, C Pilcher, D Margolis, P Leone, S Fiscus, G Ferrari, C Hicks, J Eron, The Duke-UNC Acute HIV Infection Consortium. &quot;Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.&quot; XVII International AIDS Conference, 2008 Abstract no. THPE0082.</citation>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <results_first_submitted>February 8, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Cynthia L Gay, MD</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Acute HIV</keyword>
  <keyword>HIV</keyword>
  <keyword>Acute Infections</keyword>
  <keyword>Acute Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals with acute HIV (AHI) detected via a statewide AHI screening program in publicly funded sites and primary care sites are reported to the NC Department of Health and Human Services (DHHS). DHHS staff immediately refer acute cases to HIV care. From Jan 2005 and Dec 2011, all AHI cases referred to UNC and Duke were offered enrollment.</recruitment_details>
      <pre_assignment_details>This was a single-arm, open-label study of emtricitabine/tenofovir/efavirenz started at enrollment. All participants received the same study treatment. Study treatment was not delayed for baseline resistance testing. Participants with transmitted baseline resistance to any drug in the regimen were followed on study on an alternative regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acute HIV Infection Treatment Group</title>
          <description>This study was a dual-center, single-arm open-label study of the safety and efficacy of once daily, FTC/TDF/EFZ administered to participants with acute HIV infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acute HIV Infection Treatment Group</title>
          <description>This study was a dual-center, single-arm open-label study of the safety and efficacy of once daily, FTC/TDF/EFZ administered to participants with acute HIV infection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>age (years) at time of acute HIV diagnosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age at enrollment</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender at birth was determined at screening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were enrolled at either The University of North Carolina or Duke University.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 cell count</title>
          <description>Baseline CD4 cell count</description>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="487" lower_limit="13" upper_limit="1316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA level</title>
          <description>baseline HIV RNA level</description>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="614898" lower_limit="615" upper_limit="29807640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sexual risk group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterosexual Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men who have sex with men</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>sexually transmitted diseases within 8 weeks prior to diagnosis</title>
          <description>Diagnosis of sexually transmitted disease within the 8 weeks prior to diagnosis with acute HIV</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Without Virologic Failure at Week 24</title>
        <description>Number of participants with a HIV RNA level &lt;200 copies/mL at week 24</description>
        <time_frame>HIV RNA level prior to or at week 24 following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Participants suppressed to &lt;200 copies/mL prior to or at week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Virologic Failure at Week 24</title>
          <description>Number of participants with a HIV RNA level &lt;200 copies/mL at week 24</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Without Virologic Failure at Week 48</title>
        <description>HIV RNA level &lt;50 copies/mL at week 48</description>
        <time_frame>HIV RNA level at week 48 following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Participants suppressed to &lt;50 copies/mL prior at week 48</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Virologic Failure at Week 48</title>
          <description>HIV RNA level &lt;50 copies/mL at week 48</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Suppression at Week 96</title>
        <description>Number of participants wtih HIV RNA level &lt;50 copies/mL at week 96</description>
        <time_frame>HIV RNA level at 96 weeks following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Participants who remained on study with viral suppression at week 96</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Suppression at Week 96</title>
          <description>Number of participants wtih HIV RNA level &lt;50 copies/mL at week 96</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications</title>
        <description>Prevalence of any of the surveillance drug resistance mutations associated with resistance to antiretroviral medications listed by the World Health Organization</description>
        <time_frame>At enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Acute HIV infection treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Baseline Genotypic Resistance to Antiretroviral Medications</title>
          <description>Prevalence of any of the surveillance drug resistance mutations associated with resistance to antiretroviral medications listed by the World Health Organization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment</title>
        <description>Baseline genotypic resistance defined as presence of any surveillance drug resistance mutation to any drug in the study treatment listed by the World Health Organization</description>
        <time_frame>At enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Baseline resistance testing was performed on all participants at enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Baseline Genotypic Resistance to One or More Antiretroviral Drugs in the Study Treatment</title>
          <description>Baseline genotypic resistance defined as presence of any surveillance drug resistance mutation to any drug in the study treatment listed by the World Health Organization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to HIV RNA Suppression &lt;50 Copies/mL</title>
        <description>Number of days from ART initiation to HIV RNA suppression &lt;50 copies/mL</description>
        <time_frame>Number of days from start of study treatment until HIV RNA suppression, assessed through week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute HIV Infection Treatment Group</title>
            <description>Participants who remained on treatment at designated time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to HIV RNA Suppression &lt;50 Copies/mL</title>
          <description>Number of days from ART initiation to HIV RNA suppression &lt;50 copies/mL</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="14" upper_limit="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each participant over the 96 weeks of the study.</time_frame>
      <desc>Adverse events were assessed at each visit and graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatrics Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acute HIV Infection Treatment Group</title>
          <description>Single-arml study of once daily emtricitabine/tenofovir/efavirenz administered to participants with acute HIV infection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Feeling Drunk</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Feeling Jittery</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Unevaluable Event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Lumbar Puncture Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Low Density Lipoprotein Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Memory Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Poor Quality Sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Tunnel Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Visual Field Defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Initial Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Obsessive Thoughts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pruritis Generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash Maculo-papular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cynthia Gay</name_or_title>
      <organization>The University of North Carolina</organization>
      <phone>919-843-2726</phone>
      <email>cynthia_gay@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

